Triple-Neg Breast Cancer

The relationship between BRCA-associated breast cancer and age factors: an analysis of the Japanese HBOC consortium database.
Okano M, Nomizu T, Tachibana K, Nagatsuka M, Matsuzaki M, Katagata N, Ohtake T, Yokoyama S, Arai M, Nakamura S.
J Hum Genet. 2020 Oct 12. doi: 10.1038/s10038-020-00849-y. Epub ahead of print.

Exploiting Chromosomal Instability of PTEN-Deficient Triple-Negative Breast Cancer Cell Lines for the Sensitization against PARP1 Inhibition in a Replication-Dependent Manner.
Cancers (Basel). 2020 Sep 29;12(10):E2809. doi: 10.3390/cancers12102809.

Management of early breast cancer in patients bearing germline BRCA mutations.
t'Kint de Roodenbeke MD, Pondé N, Buisseret L, Piccart M.
Semin Oncol. 2020 Aug 18:S0093-7754(20)30083-X. doi: 10.1053/j.seminoncol.2020.07.006. Epub ahead of print.

LitAlert ~~ GeneLit.com

The dawn of targeted therapies for triple negative breast cancer (TNBC): a snapshot of investigational drugs in phase I and II trials.
Huynh MM, Pambid MR, Jayanthan A, Dorr A, Los G, Dunn SE.
Expert Opin Investig Drugs. 2020 Sep 1. doi: 10.1080/13543784.2020.1818067. Epub ahead of print.

Biomarkers in Breast Cancer: An Integrated Analysis of Comprehensive Genomic Profiling and PD-L1 Immunohistochemistry Biomarkers in 312 Patients with Breast Cancer.
Huang RSP, Li X, Haberberger J, Sokol E, Severson E, Duncan DL, Hemmerich A, Edgerly C, Ferguson NL, Williams E, Elvin J, Vergilio JA, Killian JK, Lin D, Hiemenz M, Xiao J, McEwan D, Holmes O, Danziger N, Erlich R, Frampton G, Cohen MB, McGregor K, Reddy P, Cardeiro D, Anhorn R, Venstrom PJ, Alexander B, Brown C, Pusztai L, Ross JS, Ramkissoon SH.
Oncologist. 2020 Sep 1. doi: 10.1634/theoncologist.2020-0449. Epub ahead of print.

Optimizing the management of HER2-negative metastatic breast cancer in the era of PARP inhibitors-proceedings from breast cancer expert group meeting.
Dawood S, Konstantinova M, Perazzo F, Kim SB, Villarreal-Garza C, Franco SX, Simon SD, El-Nahas T.
Chin Clin Oncol. 2020 Aug 17:cco-20-138. doi: 10.21037/cco-20-138. Epub ahead of print.

TBCRC 030: A phase II study of preoperative cisplatin vs. paclitaxel in triple-negative breast cancer: evaluating the homologous recombination deficiency (HRD) biomarker.
Mayer EL, Abramson V, Jankowitz R, Falkson C, Marcom PK, Traina T, Carey L, Rimawi M, Specht J, Miller K, Stearns V, Tung N, Perou C, Richardson AL, Componeschi K, Trippa L, Tan-Wasielewski Z, Timms K, Krop I, Wolff AC, Winer EP.
Ann Oncol. 2020 Aug 13:S0923-7534(20)42061-7. doi: 10.1016/j.annonc.2020.08.2064. Epub ahead of print.

Effect of Adjuvant Paclitaxel and Carboplatin on Survival in Women With Triple-Negative Breast Cancer: A Phase 3 Randomized Clinical Trial.
Yu KD, Ye FG, He M, Fan L, Ma D, Mo M, Wu J, Liu GY, Di GH, Zeng XH, He PQ, Wu KJ, Hou YF, Wang J, Wang C, Zhuang ZG, Song CG, Lin XY, Toss A, Ricci F, Shen ZZ, Shao ZM.
JAMA Oncol. 2020 Aug 13. doi: 10.1001/jamaoncol.2020.2965. Epub ahead of print.

Effect of Adjuvant Paclitaxel and Carboplatin on Survival in Women With Triple-Negative Breast Cancer: A Phase 3 Randomized Clinical Trial.
Yu KD, Ye FG, He M, Fan L, Ma D, Mo M, Wu J, Liu GY, Di GH, Zeng XH, He PQ, Wu KJ, Hou YF, Wang J, Wang C, Zhuang ZG, Song CG, Lin XY, Toss A, Ricci F, Shen ZZ, Shao ZM.
JAMA Oncol. 2020 Aug 13. doi: 10.1001/jamaoncol.2020.2965. Epub ahead of print.

Biology of the Triple-Negative Breast Cancer: Immunohistochemical, RNA, and DNA Features.
Herrera Juarez M, Tolosa Ortega P, Sanchez de Torre A, Ciruelos Gil E.
Breast Care (Basel). 2020 Jun;15(3):208-216. doi: 10.1159/000508758. Epub 2020 Jun 5.

Impact of the addition of carboplatin to anthracycline-taxane-based neoadjuvant chemotherapy on survival in BRCA1/2-mutated triple-negative breast cancer.
Zhang J, Yao L, Liu Y, Ouyang T, Li J, Wang T, Fan Z, Fan T, Lin B, Xie Y.
Int J Cancer. 2020 Jul 28. doi: 10.1002/ijc.33234. Epub ahead of print.